ATE322894T1 - Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten - Google Patents

Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Info

Publication number
ATE322894T1
ATE322894T1 AT02716434T AT02716434T ATE322894T1 AT E322894 T1 ATE322894 T1 AT E322894T1 AT 02716434 T AT02716434 T AT 02716434T AT 02716434 T AT02716434 T AT 02716434T AT E322894 T1 ATE322894 T1 AT E322894T1
Authority
AT
Austria
Prior art keywords
carbostyril derivatives
subtype agonists
substituted carbostyril
ht1a subtype
ht1a
Prior art date
Application number
AT02716434T
Other languages
English (en)
Inventor
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Yasufumi Uwahodo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE322894T1 publication Critical patent/ATE322894T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02716434T 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten ATE322894T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29

Publications (1)

Publication Number Publication Date
ATE322894T1 true ATE322894T1 (de) 2006-04-15

Family

ID=25087808

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06015782T ATE504293T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung
AT02716434T ATE322894T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
AT05023971T ATE362763T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06015782T ATE504293T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05023971T ATE362763T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Country Status (19)

Country Link
EP (3) EP1712225B1 (de)
JP (4) JP4178032B2 (de)
KR (5) KR100763288B1 (de)
CN (3) CN1239154C (de)
AR (4) AR032641A1 (de)
AT (3) ATE504293T1 (de)
AU (4) AU2002226752C1 (de)
BR (1) BR0206237A (de)
CA (2) CA2700314C (de)
CY (3) CY1105631T1 (de)
DE (3) DE60220325T2 (de)
DK (3) DK1621198T3 (de)
ES (3) ES2363366T3 (de)
MX (2) MXPA03006603A (de)
MY (1) MY129355A (de)
PH (1) PH12014500937A1 (de)
PT (3) PT1712225E (de)
TW (2) TWI302832B (de)
WO (1) WO2002060423A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
EP1551393A4 (de) * 2002-07-30 2010-06-16 Peter Migaly Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05012538A (es) * 2003-05-23 2006-02-22 Otsuka Pharma Co Ltd Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo.
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
ES2646326T3 (es) * 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (de) 2009-12-22 2011-06-29 Gmeiner, Peter Neue Aminotetralinderivate
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
US4764416A (en) 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
EP0586525B1 (de) * 1991-05-20 1997-04-16 PHARMACIA & UPJOHN COMPANY Karboxamido-(1,2n)-karbocyclo-2-aminotetralinderivate
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
IL126590A (en) * 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
ES2188970T3 (es) * 1996-08-27 2003-07-01 Wyeth Corp 4-aminoetoxiindoles, como agonistas d2 de dopamina y como ligandos de los receptores 5ht1a.
CN1289333A (zh) * 1998-02-03 2001-03-28 美国家用产品公司 用作血清素－1a受体激动剂的噁唑衍生物
AU3555099A (en) * 1998-04-13 1999-11-01 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
EP1397145B1 (de) * 2001-06-19 2006-09-06 Norbert Müller Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
CA2429496C (en) 2010-10-19
CA2429496A1 (en) 2002-08-08
AU2007201701B2 (en) 2010-06-17
EP1621198A2 (de) 2006-02-01
DE60220325D1 (de) 2007-07-05
KR20060028485A (ko) 2006-03-29
CY1105631T1 (el) 2010-12-22
EP1712225A1 (de) 2006-10-18
AU2005201772C1 (en) 2010-06-03
AU2002226752C1 (en) 2010-02-18
DK1621198T3 (da) 2007-09-24
JP5683010B2 (ja) 2015-03-11
KR20070065425A (ko) 2007-06-22
AU2009233591A1 (en) 2009-11-19
CN100450485C (zh) 2009-01-14
AU2005201772A1 (en) 2005-05-19
AU2002226752B2 (en) 2005-03-17
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
KR20030065570A (ko) 2003-08-06
ES2286755T3 (es) 2007-12-01
PT1355639E (pt) 2006-06-30
TWI302832B (en) 2008-11-11
DK1712225T3 (da) 2011-06-20
EP1712225B1 (de) 2011-04-06
DE60210581D1 (en) 2006-05-24
HK1091403A1 (zh) 2007-01-19
JP4178032B2 (ja) 2008-11-12
JP2011184460A (ja) 2011-09-22
MXPA03006603A (es) 2004-02-12
DE60239711D1 (de) 2011-05-19
PT1621198E (pt) 2007-06-08
TW200522960A (en) 2005-07-16
HK1061805A1 (en) 2004-10-08
CN1484524A (zh) 2004-03-24
MX344556B (es) 2016-12-20
AR099754A2 (es) 2016-08-17
ES2261652T3 (es) 2006-11-16
CA2700314C (en) 2012-04-24
AR032641A1 (es) 2003-11-19
AU2007201701A1 (en) 2007-05-10
DK1355639T3 (da) 2006-08-14
EP1621198B1 (de) 2007-05-23
CY1111392T1 (el) 2015-08-05
PT1712225E (pt) 2011-04-18
WO2002060423A3 (en) 2003-04-10
CN1239154C (zh) 2006-02-01
KR20050107822A (ko) 2005-11-15
JP2011225587A (ja) 2011-11-10
EP1621198A3 (de) 2006-04-12
EP1355639B1 (de) 2006-04-12
KR100763288B1 (ko) 2007-10-04
CA2700314A1 (en) 2002-08-08
JP2004517937A (ja) 2004-06-17
AR080849A2 (es) 2012-05-09
CY1108031T1 (el) 2013-09-04
AU2005201772B2 (en) 2007-05-17
ES2363366T3 (es) 2011-08-02
DE60220325T2 (de) 2008-01-17
KR100825705B1 (ko) 2008-04-29
ATE362763T1 (de) 2007-06-15
KR100601073B1 (ko) 2006-07-19
EP1355639A2 (de) 2003-10-29
JP4896831B2 (ja) 2012-03-14
MY129355A (en) 2007-03-30
KR100653591B1 (ko) 2006-12-05
DE60210581T2 (de) 2007-04-05
BR0206237A (pt) 2003-12-23
KR100713607B1 (ko) 2007-05-02
KR20060085260A (ko) 2006-07-26
CN1879624A (zh) 2006-12-20
JP2007297405A (ja) 2007-11-15
WO2002060423A2 (en) 2002-08-08
ATE504293T1 (de) 2011-04-15
PH12014500937A1 (en) 2015-09-21
TWI331919B (en) 2010-10-21
CN1813745A (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
DE60220325D1 (de) Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE392897T1 (de) Chinolinderivate als npy antagonisten
DE60317365D1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
ATE414067T1 (de) Guanidinobenzamide als mc4-r agonisten
IS8439A (is) Nýjar kínólín afleiður
ATE370120T1 (de) Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
DE60308850D1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
DE60226775D1 (de) Azaindolylalkylaminderivate als 5-hydroxytryptamin-6-liganden
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
ATE413879T1 (de) ß(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)- ETHYLAMINO)- PROPYLPHENYL-DERIVATE ALS BETA2 AGONISTEN
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE308325T1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
ATE395333T1 (de) 4-phenylpiperazinyl, -piperidinyl und - tetrahydropyridyl-derivate als dopamin d4- antagonisten
ATE281435T1 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DE60129445D1 (de) Quinolin-derivate als antientzündungsmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355639

Country of ref document: EP